Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BSX 
Boston Scientific Corp (BSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: BSX (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
34 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $124.89
1 Year Target Price $124.89
| 23 | Strong Buy |
| 8 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.45% | Avg. Invested days 66 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 141.37B USD | Price to earnings Ratio 56.79 | 1Y Target Price 124.89 |
Price to earnings Ratio 56.79 | 1Y Target Price 124.89 | ||
Volume (30-day avg) 34 | Beta 0.61 | 52 Weeks Range 80.64 - 109.50 | Updated Date 10/12/2025 |
52 Weeks Range 80.64 - 109.50 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.55% | Operating Margin (TTM) 18.63% |
Management Effectiveness
Return on Assets (TTM) 5.39% | Return on Equity (TTM) 11.55% |
Valuation
Trailing PE 56.79 | Forward PE 28.49 | Enterprise Value 154067142223 | Price to Sales(TTM) 7.64 |
Enterprise Value 154067142223 | Price to Sales(TTM) 7.64 | ||
Enterprise Value to Revenue 8.33 | Enterprise Value to EBITDA 33.16 | Shares Outstanding 1481751634 | Shares Floating 1477454554 |
Shares Outstanding 1481751634 | Shares Floating 1477454554 | ||
Percent Insiders 0.19 | Percent Institutions 93.4 |
Upturn AI SWOT
Boston Scientific Corp
Company Overview
History and Background
Boston Scientific Corp. was founded in 1979. It has grown through innovation and acquisitions to become a major player in the medical device industry, focusing on less-invasive medical technologies.
Core Business Areas
- MedSurg: Endoscopy, urology, and pelvic health solutions. Focus on minimally invasive procedures.
- Cardiology: Interventional cardiology and cardiac rhythm management. Includes devices for coronary artery disease and heart rhythm disorders.
- Neuromodulation: Chronic pain management and deep brain stimulation therapies.
Leadership and Structure
Geoff Martha is the current Chairman and CEO. The company operates with a functional organizational structure, with global business units and centralized support functions.
Top Products and Market Share
Key Offerings
- WATCHMAN FLX Left Atrial Appendage Closure Device: A device designed to close off the left atrial appendage in patients with non-valvular atrial fibrillation to reduce the risk of stroke. Market share data is proprietary, but the device holds a significant portion of the LAAC market. Competitors include Abbott's Amulet and Johnson & Johnson's Biosense Webster.
- POLARx Cryoablation System: A cryoablation system used to treat atrial fibrillation by freezing heart tissue to block irregular electrical signals. Market share data is proprietary, but the device holds a significant portion of the Cryoablation market. Competitors include Medtronic and Biosense Webster.
- Vercise Genus Deep Brain Stimulation (DBS) System: A system for treating symptoms of Parkinson's disease, dystonia, and essential tremor. Market share data is proprietary, but the device holds a significant portion of the DBS market. Competitors include Medtronic and Abbott.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and demographic trends, such as an aging population, driving demand for medical technologies.
Positioning
Boston Scientific Corp is a leader in less-invasive medical devices and therapies, with a strong portfolio and global presence. Its competitive advantages include its innovation pipeline, sales network, and strong relationships with healthcare providers.
Total Addressable Market (TAM)
The global medical device market is estimated to be valued at approximately $550 billion USD and is expected to grow. Boston Scientific Corp is positioned to capture a significant share of this TAM through its diverse product portfolio and strategic investments.
Upturn SWOT Analysis
Strengths
- Strong Product Portfolio
- Global Presence
- Innovation Pipeline
- Established Sales Network
- Strong Brand Recognition
Weaknesses
- Reliance on Innovation
- Exposure to Regulatory Risks
- Integration Challenges with Acquisitions
- Price pressures from healthcare cost containment
Opportunities
- Expanding into Emerging Markets
- Developing New Technologies
- Acquiring Complementary Businesses
- Partnering with Healthcare Providers
Threats
- Increased Competition
- Changing Healthcare Regulations
- Economic Downturns
- Product Liability Claims
Competitors and Market Share
Key Competitors
- MDT
- ABT
- JNJ
Competitive Landscape
Boston Scientific competes with other major medical device companies based on product innovation, pricing, and market access. BSX has a strong focus on less-invasive procedures and has a global reach.
Major Acquisitions
Apollo Endosurgery
- Year: 2023
- Acquisition Price (USD millions): 615
- Strategic Rationale: Expands Boston Scientific's endoscopy portfolio with innovative solutions for bariatric and gastrointestinal procedures.
Growth Trajectory and Initiatives
Historical Growth: Boston Scientific has experienced growth through organic innovation and strategic acquisitions.
Future Projections: Analyst estimates project continued growth driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include acquisitions of companies with complementary technologies and expansion into new markets.
Summary
Boston Scientific is a strong player in the medical device industry, driven by its innovative technologies and strategic acquisitions. While facing competition and regulatory hurdles, the company benefits from a diverse product portfolio and global presence. Continued innovation and market expansion are key to maintaining its growth trajectory. Investors should consider regulatory risks and integration challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on available estimates and may vary. Financial data requires live updates to be accurate. This analysis is based on publicly available information and assumptions and may not be completely accurate or comprehensive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boston Scientific Corp
Exchange NYSE | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1992-05-18 | Chairman, President & CEO Mr. Michael F. Mahoney | ||
Sector Healthcare | Industry Medical Devices | Full time employees 53000 | Website https://www.bostonscientific.com |
Full time employees 53000 | Website https://www.bostonscientific.com | ||
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.